



ZAMIVET 80

ZAMIVET 80

80g/1kg enramycin

Overview


1. Enramycin
2. Chemical Structure
3. Mechanism of action
4. Activity Spectrum of Anti-Infectives
5. Overview : Benefits of enramycin
 - Disease Control
 - Performance Improvements
 - Environmental Benefits
 - Other Benefits
6. Summary
7. What is a veterinary feed directive (VFD)?
8. Product Introduction – ZAMIVET40
9. Applications
10. Quality Indicators



Polypeptide Antibiotic

Polypeptide

- a chain of amino acids linked together by peptide bonds




Polypeptide Antibiotic

Non-ribosomally synthesized peptides


- Largely produced by bacteria, fungi, and streptomycetes
- Major component of the natural host defense molecules of these species.
- Anti-infective and antitumor antibiotics

Enramycin

Enramycin is a **polypeptide antibiotic** produced by *Streptomyces fungicidus*



Chemical Structure




Enramycin


Mechanism of action

- Acts as a **MurG inhibitor** involved peptidoglycan synthesis in Gram positive bacteria.
- MurG catalyzes the transglycosylation reaction in the last step of **peptidoglycan biosynthesis**.
- Inhibition of this step greatly compromises cell wall integrity leading to **cell lysis**.
- Active within the **gastrointestinal tract** where it modifies the intestinal flora and **maintains the integrity of the gut**.


Bacterial Cell Wall



GRAM-POSITIVE




Mechanism of action




Compromises cell wall integrity leading to **cell lysis**

Activity Spectrum of Anti-Infectives


Gram Positive




Staphylococci



Streptococci



Corynebacterium



Clostridium

Enramycin



- **Not absorbed** from the intestinal tract
- High **safety** margin
- **No cross-resistance** between enramycin and other available antibiotics
- No detectable **residue** in tissues

Overview : Benefits of Enramycin



1. Disease Control
2. Performance Improvements
3. Environmental Benefits
4. Other benefits

Disease Control

Disease Control




- Necrotic enteritis in poultry
- Clostridial enteritis in piglets
- Swine dysentery

Disease Control Poultry






Necrotic Enteritis

- Necrotic enteritis (NE) is an enteric bacterial disease of poultry caused by *Clostridium perfringens*.
- Necrotic enteritis in poultry is caused by *Clostridium perfringens* type A & C.
- The disease is characterized by damage to the intestinal mucosa by **toxins** produced by *Clostridium perfringens*.
- **Mild** or **subclinical form** of NE is associated with poor growth and feed utilization.




Clinical Signs & Lesions




Various Predisposing Factors for Necrotic Enteritis

Risk factor	Reference
Infectious	
Coccidiosis (<i>Eimeria</i> infection)	Long, 1973; Alsheikhly & Alsaieg, 1980; Baba <i>et al.</i> , 1992; Baba <i>et al.</i> , 1997; Hofacre <i>et al.</i> , 1998a
Immunosuppression	McReynolds <i>et al.</i> , 2004b
Non-infectious	
Fish meal	Wijewant & Senevira, 1971b
Barley	Riddell & Kong, 1992; Kaldhusdal & Skjerve, 1996; Annett <i>et al.</i> , 2002
Wheat	Branton <i>et al.</i> , 1987; Riddell & Kong, 1992; Kaldhusdal & Skjerve, 1996 Annett <i>et al.</i> , 2002
Increased digesta viscosity (NSPs)	Kosher, 2003
Lipids	Dahiya <i>et al.</i> , 2006
Dietary protein	Truscott & Alsheikhly, 1977; Kaldhusdal & Skjerve, 1996; Drew <i>et al.</i> , 2004; Dahiya <i>et al.</i> , 2005a; Wilkie <i>et al.</i> , 2005;
Managment	
Litter	Cowen <i>et al.</i> , 1987; Droual <i>et al.</i> , 1994; Williams, 2005; Hermans & Morgan, 2007; Mikkelsen <i>et al.</i> , 2009; Palliyeguru <i>et al.</i> , 2010


Immunological Equilibrium - Clostridial Enteropathies




Necrotic enteritis : Disease Induction & Predisposing Factors




Clostridial Proliferation and Intestinal Instability




Oocysts per gram of litter by flock age



Oocysts per gram of litter by flock age




Impact of Clostridial enteritis on the daily gain & performance of broilers




	Mortality	Body weight gain	FCR units
Clinical	Up to 30% of flock		
	3 to 7% of flock		+> 0,7
	+1% versus control	-5%	+0,05 - 0,1
Subclinical	+0,8% versus control	-4%	+0,04 - 0,08

Role of coccidiosis in Necrotic Enteritis



Predisposing Factors for Necrotic Enteritis



2015 Top 10 Broiler Health Issues Surveyed

Ranking	Philippines	Thailand	Japan	China	Korea	Vietnam	India	Indonesia	Asia
1	CRD	ND	Colibacillosis	AI(LP,HP)	Chick quality	HPAI	CAstV	ND	CRD
2	Chick quality	IB	RVR	IB	IB	ND	CRD	AI	IB
3	RVR	CRD	BMM	CRD	Lameness (Infectious)	IBD	AI	CRD	AI
4	RSS	MG	Metabolic issues	RVR	Cocci	IB	RSS	Gut health	ND
5	Gut health	MS	Chick quality	MG	DOA	CRD	IB	RVR	Chick quality
6	DOA	IBD	Cocci	MS	Metabolic issues	MG	FAdV	Chick quality	RVR
7	IB	Cocci	NE/GD	FAdV	IBD	MS	IBD	Metabolic issues	Cocci
8	ND	Lameness (Infectious)	HPAI	Cocci	FAdV	Cocci	Mycotoxin	SMS	IBD
9	Lameness (Structural)	FAdV	Lameness (Infectious)	Gut health	NE/GD	Gut health	Cocci	Cocci	MG
10	CAV	RVR	IBD	Chick quality	Salmonellosis	Mycotoxin	NE/GD	IBD	Gut health

CRD is including colibacillosis, RVR: Respiratory Vaccine Reaction, RSS: Runting and Stunting Syndrome, DOA: Dead On Arrival in slaughter house, BMM: Breast Muscle Myopathy, Metabolic issues include Ascites and SDS

2015 Top 10 Broiler Breeder Health Issues Surveyed

Ranking	Philippines	Thailand	Japan	China	Korea	Vietnam	India	Indonesia	Asia
1	FC	ND	RT	AI(LP,HP)	RT	HPAI	MD	Metabolic disorder	IB
2	SMS	IB	NE/GD	IB	EYP	ND	IB	Gut health	AI
3	Cocci	MG	Cocci	Lameness (Infectious)	IB	IB	CAV	EYP	EYP
4	Chick quality	MS	Lameness (Infectious)	EYP	HPAI	MG	NE/GD	Lameness (Infectious)	Cocci
5	ILT	Gut health	Red mite	Cocci	APV	MS	MG	NE/GD	Gut health
6	IC	EYP	EYP	MG/MS	Gut health	FAdV	IBD	Trauma	MG
7	Gut health	Cocci	Chick quality	Gut health	MS	APV	ND	Cocci	NE/GD
8	NE/GD	Chick quality	Metabolic disorder	APV	REO	CAV	FAdV	FC	ND
9	Lameness (Nutrition)	Aspergilliosis	HPAI	MD	Metabolic disorder	Salpingitis	ILT	Parasite	MS
10	Parasite	FAdV	FAdV	Salmonellosis	Chick quality	Salmonellosis	Metabolic disorder	IBV	Lameness (Infectious)

FC: Fowl Cholera, SMS: Spiking mortality syndrome, IC: Infectious Coryza, NE: Necrotic Enteritis, GD: Gangrenous Dermatitis, EYP: Egg Yolk Peritonitis, FAdV: Fowl Adenovirus, RT: Ruptured Tendon

Disease Control Swine



Evolution of Piglet Intestinal Flora



Before Birth

Digestive system is sterile



During Lactation

Small Intestine

- Lactobacillus
- Streptococcus

Large Intestine

- Anaerobic Gram positives



After Weaning


Small intestine

- Higher proportion of coliforms

Large Intestine

- Gram negative

Intestinal normal flora takes some time to be 100% balanced and functional



Small Intestine
7 days after weaning

Large Intestine
20 days after weaning

Population of enteric bacterial in the intestine is affected by

1. Nutritional factors

- **Feed** and **litter contaminated** with large numbers of pathogenic enteric bacteria have been convincingly implicated as a source of infection

2. Environmental factors

3. Health status of the gut of the pig

Various Predisposing Factors for Swine Enteric Bacterial Infection

Non - Infectious

Feed

- Structure and pellet quality
- Palatability
- Formulation and content
- Mycotoxins

Management

- Available feed space
- Available water space
- Distribution of waterers
- Water quality
- Air quality
- Temperature
- Stocking density

Infectious

Viral Agent

- Rotavirus
- Coronavirus
- Circovirus

Bacterial Agent

- Clostridium
- *Brachyspira*
- E.coli

Parasites

- *Cryptosporidium* sp
- *Isospora suis*
- *Trichuris suis*

Non-infectious Diarrhea

- Inflammation **without** pathogen detection
- Disruption in the intestinal
 - Diet change
 - Diets ingredient change
 - Water quality
 - Mineral levels or mycotoxins

Epidemiology of Enteric Bacterial Infection



Transmission of infection between **pigs** and the **environment**




Transmission of enteric bacteria from **sows** to **their progeny**



External vectors in transmission of enteric bacteria

Pathogenesis of Disease: Interactions Between Pathogens, Host, and Environment



The Main Causes Of Piglet Diarrhoea

	Early Period Days		Late Period Days		Mortality Level
	0-3	3-7	7-14	15-21	
Agalactia	●	●	●	●	Moderate
Clostridia	●	●	●		High
Coccidiosis		●	●	●	Low
Colibacillosis	●	●	●		Moderate
PED	●	●	●	●	Low
PRRS	●	●	●	●	Variable
Rotavirus			●	●	Low
TGE	●	●	●	●	High

Age Distribution of Diarrheal Diseases in Pigs

Enteric Bacterial Disease

	Age Group		
	Nursing	Weaning	Growing Finishing Breeding
Clostridium difficile enteritis	↑↑↑	↑	↑
Clostridium perfringens type A enteritis	↑↑	↑	-
Clostridium perfringens type C enteritis	↑↑	-	-
Enteric colibacillosis	↑↑↑	↑↑↑	-
Intestinal spirochetosis	-	↑↑	↑↑↑
Porcine proliferative enteritis	-	↑↑	↑↑↑
Salmonella enteritis	↑	↑↑	↑↑↑
Swine dysentery	↑	↑↑	↑↑↑

D.L.H. Harris (2013)


[-] Rare or does not occur

[↑] Uncommon

[↑↑] Common

[↑↑↑] Very common

Impact on Animal Performance



Clinical Findings




Clinical Findings




Porcine proliferative enteritis



Catarrhal Colitis



Swine Dysentery



Clostridium perfringens
type C enteritis



Clostridium perfringens
type A enteritis



Porcine proliferative enteritis

Important Pig Diseases in SEA

Table 6. Important pig diseases currently endemic in Southeast Asia.

Diseases and pathogen	Transmissible	Diseases and pathogen	Transmissible
Enzootic Pneumonia	Zoonose	Epidemic Diarrhea	
Pasteurellosis		Transmissible gastroenteritis	
Porcine Pleuropneumonia		Round Worm	
Bordetella		Oesophagostomiasis	
Atrophic Rhinitis		Leptospirosis	Zoonose
Porcine Respiratory Coronavirus		Brucellosis	Zoonose
Swine influenza	Zoonose	Parvovirus	
Glassers Disease		Porcine Reproductive and Respiratory Syndrome	
Streptococcus meningitis	Zoonose	Erysipelas	
Lungworm		Tuberculosis	Zoonose
Colibacillosis	Zoonose	Exudative Epidermitis	
Oedema Disease		Mange	
Salmonellosis	Zoonose	Encephalomyocarditis	Zoonose
Rotavirus		Nipah Encephalitis	Zoonose
Coccidiosis		Foot and Mouth Disease	
Swine Dysentery		Swine Vesicular Disease	Zoonose
Spirochaetal diarrhoea	Zoonose	Pseudorabies	
Proliferative Enteropathy		Classical Swine Fever	
		Japanese Encephalitis	Zoonose

Source: Cameron (2000).

Performance Improvements

Performance Improvements



Poultry

- Prevents necrotic enteritis in poultry.
- Has been shown to treat necrotic enteritis in broilers.
- Significantly reduces environmental loading of excreta and nitrogen.
- Increased rate of bodyweight gain.
- Lower feed requirements for each unit of gain.

Environmental Benefits

Reduced nitrogen excretion (all species)

Increase the **efficiency of nutrient utilisation**, improving retention of N and P and **decreasing excretion** when nutrient intake matches requirements.

1. **Decrease microbial degradation** of essential amino acid
2. **Improve absorption**, enabling amino acid utilisation
3. Reductions in **nitrogen excretion**.
4. **Ammonia gas emission** from the **manure** was markedly **decreased** by feeding these lower-protein diets

Other Benefits




Other Benefits



- Protein sparing
- Energy sparing
- Improved mineral absorption
- Improved immune status
- Drier litter and reduced foot problems

Production and Economic Impacts

The Real Silent Performance Killer



Impact on Poultry Performance

- High mortality rate : up to **30%** of the flock.
- Subclinical level:
 - FCR to increase with **6-9 points** & final bodyweight to reduce between **3-5%**
- Annual losses to producers due to **subclinical NE:**
 - Est. **US\$0.015 cent** to **US\$0.05 cent per birds** (2000)

Economical Importance in Poultry Industry



- NE occurs worldwide and causes considerable **financial losses** to poultry producers due to **mortality and treatment cost**.
- Producer often adopt the figure of **USD 0.05 per chick** derived from a **USD 2 billion loss** on a worldwide scale estimated in 2000.
- Since then, parameter have changed, as have the true costs of NE, would come closed to **US\$6 billion** in 2015.
- A later study found that the cost was closer to **US\$0.625 per bird**.

Due to:

1. Increased mortality.
2. Increased feed conversion ratio.
3. Decreased weight gain.

Production and Economic Impacts of Swine Enteric Bacterial Infection

Subclinical infections

- Diarrhoea is **rarely observed** in pigs sub-clinically affected with bacterial infections
- Decreased **feed intake**
- Reduce pig weights or **weight gains**
- **Variation** in pig weights (increased in infected pigs relative to non-infected pigs)
- Reductions in **ADG** and increased **FCR**
- The economic impact of sub-clinical infection is **difficult to estimate** because many producers are **unaware** that sub-clinical infection is present in their herd.

Production and Economic Impacts of Swine Enteric Bacterial Infection

Enteric bacterial infections occur worldwide and causes considerable **financial losses** to swine producers due to morbidity, mortality and treatment cost.

Due to:

1. Increased mortality.
2. Increased feed conversion ratio.
3. Decreased weight gain.

	Sow infected	Nursing/Grower/Finisher	
		Morbidity	Mortality
Swine dysentery	Up to 25%	75 - 90%	25 - 30%
Clostridium difficile enteritis		7 - 10%	Up to 50%
Clostridium perfringens type A enteritis		> 90%	< 1%
Porcine proliferative enteritis		10 - 15%	50%
Intestinal Spirochetosis		5 - 15%	1 - 2%

Summary



Benefits in poultry

- Improves **liveweight gain** and **feed conversion efficiency** of broilers.
- **Prevents necrotic enteritis** in broilers and caged birds.
- Has been shown to **treat necrotic enteritis** in broilers.
- Significantly **reduces environmental loading of excreta** and **nitrogen**.

Summary



Benefits in pigs

- Improves the **growth rate and feed conversion efficiency** of treated pigs.
- Treatment of pregnant sows decreased the incidence and severity of **clostridial enteritis in their piglets**.
- Treated sows **lose less weight and wean greater numbers of heavier piglets**.
- Controls **swine dysentery (SD)** in growing-finishing pigs.

What is a veterinary feed directive (VFD)?

FDA – Veterinary Feed Directive (VFD)



What is a veterinary feed directive?

In United States agricultural policy, a Veterinary Feed Directive (VFD) is

- a **written statement** that **authorizes** the owner or caretaker of animals to **obtain and use animal feed containing VFD drugs** to treat their animals
- in accordance with the **FDA-approved** directions for use.

FDA – Veterinary Feed Directive (VFD)



What is a VFD drug?

A VFD drug is

- intended for use in **animal feeds**
- VFD drug is permitted only **under the professional supervision** of a licensed veterinarian.

FDA – Veterinary Feed Directive (VFD)



Over-the-counter medicine

- Is also known as OTC or **non-prescription** medicine
- Refer to medicine that you can buy **without** a prescription
- They are **safe** and **effective** when you follow the directions on the label and as directed by your health care professional

FDA – Veterinary Feed Directive (VFD)



National Grain
and Feed Association

FDA's Antimicrobial Resistance Policies and the Veterinary Feed Directive

Impacts on Medicated Feed

July 2016



FDA – Veterinary Feed Directive (VFD)

Unaffected by FDA proposals

Animal use only

Drugs used exclusively in animals:

- Ionophores
- Polypeptides
- Carbadox
- Bambermycin
- Pleuromutilin

Human use only

Drugs used exclusively in humans:

- Daptomycin
- Glycylcyclines
- Mupirocin
- Mycobacterium anti-infectives

Affected by FDA proposals

Shared use

Drugs deemed “important for human medicine” and used by both animals and humans, such as:

- Penicillins
- Cephalosporins
- Quinolones
- Fluoroquinolones
- Tetracyclines
- Macrolides
- Sulfas
- Glycopeptides
- Others

Therapeutic uses

(still allowed under veterinary supervision)

Treat animals diagnosed with an illness

Control the spread of illness in a herd

Prevent illness in healthy animals when exposure is likely

Production uses

(No longer allowed)

Enhance growth or improve feed efficiency

OIE List of Antimicrobial Agents of Veterinary Importance



ANTIMICROBIAL AGENTS (CLASS, SUB-CLASS, SUBSTANCE)	SPECIES	Specific comments	VCIA	VHIA	VIA
POLYPEPTIDES					
Enramycin	Avian, Swine, Bovine, Rabbit, Ovine	<p>Bacitracin is used in the treatment of necrotic enteritis in poultry.</p> <p>This class is used in the treatment of septicaemias, colibacillosis, salmonellosis, and urinary infections.</p>		X	

VCIA: Veterinary Critically Important Antimicrobial Agents
 VHIA: Veterinary Highly Important Antimicrobial Agents
 VIA: Veterinary Important Antimicrobial Agents

Maximum Residue Limits (MRLs) and Risk Management Recommendations (RMRs) for Residues of Veterinary Drugs in Foods

CODEX ALIMENTARIUS
INTERNATIONAL FOOD STANDARDS



Food and Agriculture
Organization of
the United Nations



World Health
Organization

E-mail: codex@fao.org - www.codexalimentarius.org

Maximum Residue Limits (MRL)

Abamectin	Gentamicin
Albendazole	Imidocarb
Amoxicillin	Isometamidium
Ampicillin	Ivermectin
Avylamycin	Lasalocid sodium
Azaperone	Levamisole
Benzylpenicillin/Procaine benzylpenicillin	Lincomycin
Carazolol	Lufenuron
Ceftiofur	Melengestrol acetate
Chlortetracycline/Oxytetracycline/Tetracycline	Monensin
Clenbuterol	Monepantel
Closantel	Moxidectin
Colistin	Narasin
Cyfluthrin	Neomycin
Cyhalothrin	Nicarbazin
Cypermethrin and alpha-cypermethrin	Phoxim
Danofloxacin	Pirlimycin
Deltamethrin	Porcine somatotropin
Derquantel	Progesterone
Dexamethasone	Ractopamine
Diclazuril	Sarafloxacin
Dicyclanil	Spectinomycin
Dihydrostreptomycin/Streptomycin	Spiramycin
Diminazene	Sulfadimidine
Doramectin	Teflubenzuron
Emamectin benzoate	Testosterone
Eprinomectin	Thiabendazole
Erythromycin	Tilmicosin
Estradiol-17beta	Trenbolone acetate
Febantel/Fenbendazole/Oxfendazole	Trichlorfon (Metrifonate)
Fluazuron	Triclabendazole
Flubendazole	Tylosin
Flumequine	Zeranol

E



Enramycin Residue Studies



Animal	Poultry			Swine		
ppm	0	20	100	0	20	100
Withdrawal period	0	0	0	0	0	0
Tissues	-	-	-	-	-	-
Blood	-	-	-	-	-	-
Muscle	-	-	-	-	-	-
Liver	-	-	-	-	-	-
Kidney	-	-	-	-	-	-
Spleen	-	-	-	-	-	-
Fat	-	-	-	-	-	-

ZAMIVET 80

80g/1kg enramycin

What is ZAMIVET80?



Is highly effective in controlling Necrotic Enteritis caused by *Clostridium perfringens*.

ZAMIVET 80 consistently and reliably increases rate of weight gain and improves the efficiency of feed utilization.

Active Constituent : 80g/1kg enramycin

Why Use ZAMIVET80?



- Highly effective for use in pigs and poultry as prevention and control of a range of enteric diseases
- Acts in very low inclusion level
- **Not absorbed** in the gut
- Promotes a healthy gastrointestinal tract, resulting in improved performance
- **Reducing ammonia levels** in the intestinal contents and blood
- No history of **resistance**
- High **safety** margin
- No antibiotic **residue** issues in meat
- **Synergist effects** when used with other antimicrobials & anticoccidials
- **Stable** during the pelleting process and in feeds
- Not used in **human** therapy

Increase profits with ZAMIVET80



Swine

- Increase piglet weaning weight
- Increase piglets weaned per sow
- Reduce sow weight loss during lactation
- Increase growth in grower/finisher pigs
- Improve feed conversion efficiency

Poultry

- Increase egg production from layers
- Increase growth from broilers
- Reduced mortality
- Improve feed conversion efficiency

Indications - Poultry



For prevention and control of Necrotic Enteritis in poultry caused by *C. perfringens* (Types A and C).

Indications - Swine



For prevention and control of *Brachyspira hyodysenteriae* and *Clostridium perfringens* in pigs

Usage



Prevention:

Prestarter/Starter:

125g/tonne of finished feed
(10 ppm) for **3-5 days**.

Grower/Finisher/Prelayer/Layer:

62.5g/tonne of finished feed (5 ppm)
for **3-5 days**.

Treatment:


250 g/tonne of finished feed
(20 ppm) for **5 – 7 days**

Usage – Poultry Program


	Phase	Inclusion rate (ppm)
Broiler	Starter	6 – 8
	Grower	4 – 6
	Finisher	3 – 4
Breeder	DOC to 4 weeks	10
	5 to 18 weeks	8
	19 to 24 weeks	6
	Production	4
Layer	Laying	5

Broilers Performance

Bodyweight Gain




FCR



■ CONTROL (ANTIBIOTIC FREE DIET) ■ ANTIBIOTIC FREE DIET + CLOSTRIDIUM PERFRINGENS CHALLENGE ■ ENRAMYCIN DIET + CLOSTRIDIUM PERFRINGENS CHALLENGE

Usage - Swine



Prevention:

Prestarter/Starter:

125 g/tonne of finished feed (10 ppm) for **3-5 days**.


Grower/Finisher:

62.5 g/tonne of finished feed (5 ppm) for **3-5 days**.



Treatment:

250 g/tonne of finished feed (20 ppm) for **5 – 7 days**


Historical Weather - Manila



Historical Weather - Davao



Temperature & Humidity Index - Poultry



Applications - Swine

	Age Group		
	Nursing	Weaning	Growing Finishing Breeding
<i>Clostridium difficile</i> enteritis	↑↑↑	↑	↑
<i>Clostridium perfringens</i> type A enteritis	↑↑	↑	-
<i>Clostridium perfringens</i> type C enteritis	↑↑	-	-
Intestinal spirochetosis	-	↑↑	↑↑↑
Porcine proliferative enteritis	-	↑↑	↑↑↑
Swine dysentery	↑	↑↑	↑↑↑
Feeding Phase	Lactation	Pre-starter / Starter	Grower, Finisher, Breeder



[-] Rare or does not occur

[↑] Uncommon

[↑↑] Common

[↑↑↑] Very common

Withdrawal Period


Swine & Poultry

Seven (7) days



Quality Indicators

Manufacturing Process Flow



MIC of fecal *Clostridium perfringens*

	MIC ₅₀	MIC ₉₀
Enramycin	0.2	0.4
Avilamycin	0.25	0.5
Virginiamycin	0.8	2
Oxytetracycline	4	16
Lincomycin	64	8
Colistin	≥100	≥100

Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism

Quality Indicators

- Zamira **certifies** every batch of **ZAMIVET80**
- All **ZAMIVET80** batches are **tested** for potency
- Guaranteed level of bacterial killing potency
- Giving end-users **confidence** in the product every time




Product – Physical Appearance



Grey to grey-brown powder

Product Stability – Assay

Enramycin Content



Specification: 90 – 110%

Packaging

25kg bags.

Multilayered polyethylene bag to ensure product stability in humid climates.

Shelf Life of 24 months.





ZAMIRA[®]
AUSTRALIA

Better animal health



Zamira Life Sciences Inc. | Units 912, 2301 Civic Place | Filinvest Corporate City, Alabang Muntinlupa City 1780, Philippines | +63 2 7 216 0621 | zamira.com.au